Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 14/20 | 0.37 |
| ▸ | CNR1 | P21554 | 11/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26326946 | 0.95 | KIF11 (0.40) | KIF11CNR2CNR1SMN1; SMN2 | |
| SCHEMBL19965715 | 0.82 | SOAT1 (0.34) | CNR2CNR1 | |
| SCHEMBL19965716 | 0.79 | SCN5A (0.36) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL21339358 | 0.79 | SMN1; SMN2 (0.35) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL19451475 | 0.78 | SMN1; SMN2 (0.33) | KIF11CNR2CNR1SMN1; SMN2 | |
| SCHEMBL20093570 | 0.78 | CNR2 (0.37) | KIF11CNR2CNR1SMN1; SMN2POLB | |
| SCHEMBL20089653 | 0.78 | KIF11 (0.43) | KIF11SMN1; SMN2 | |
| SCHEMBL19059646 | 0.76 | SMN1; SMN2 (0.35) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL20646806 | 0.76 | CNR2 (0.45) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL26053254 | 0.75 | SMN1; SMN2 (0.36) | CNR2CNR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | KIF11 3776/4885CNR2 528/4885CNR1 864/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | KIF11 3776/4885CNR2 528/4885CNR1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.